Abstract: The invention relates to a polyoxometalate topical composition for removing a contaminant from an environment, comprising a topical carrier and at least one polyoxometalate, with the proviso that the polyoxometalate is not H5PV2Mo10O40; K5Si(H2O)MnIIIW11O39; K4Si(H2O)MnIVW11O39; or K5CoIIIW12O40. The invention further relates to a method for removing a contaminant from an environment, comprising contacting the polyoxometalate topical composition of the present invention with the environment containing the contaminant for a sufficient time to remove the contaminant from the environment. The invention further relates to a modified polyoxometalate, wherein the modified polyoxometalate comprises the admixture of (1) a polyoxometalate and (2) a cerium compound, a silver compound, a gold compound, a platinum compound, or a combination thereof.

Abstract: A method of replacing iron losses during dialysis of patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis solutions, during dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidial ferric compound, preferably ferric pyrophosphate.

Abstract: A method of treating solid neoplastic diseases is disclosed, which involves administering to a host in need of such treatment an effective amount of a pharmaceutically acceptable magnesium salt or complex, which can be a pharmaceutically acceptable inorganic magnesium salt such as magnesium pyrophosphate, or a pharmaceutically acceptable organic magnesium salt. The composition can be administered orally, parenterally, cutaneously or mucosally, and can be given, for example, in an amount of magnesium which is from 2 to 12 mg per kg of body weight daily. Preferred compositions include magnesium lactate, magnesium aspartate, magnesium acetate, and magnesium pyrophosphate. Neoplastic diseases amenable to the method include adenocarcinoma. The method can include administering with the magnesium salt or complex an effective amount of a pharmaceutically acceptable magnesium fixing substance, such as vitamin B6.

Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among children.

Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among adolescents.

Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.

Abstract: This invention provides a method of treating an animal with pyrophosphate gout or osteoarthritis comprising administering an effective amount of a calcium antagonist, thereby reducing calcium pyrophosphate crystal deposition in the animal.

Abstract: In order to lower the painfulness of injection of the remedy containing the products of lignin basic hydrolysis and oxidation, pyrophosphate, NaCl and water the value of pH of the remedy is adjusted to a neutral one by the addition of HCl.

Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response to a meal by feeding an acid controlled induced viscosity fiber system. The first component of the induced viscosity fiber system is anionic soluble fiber. The second component of the induced viscosity fiber system is water-insoluble, acid-soluble multivalent cations. The fiber system will typically be incorporated into a meal replacement nutritional.

Abstract: What is shown is an animal blood anticoagulant compound useful in the meat packing industry generally, and in slaughterhouse operations, particularly. The anticoagulant is effective when diluted with water at higher dilution ratios than earlier anticoagulants. In some field trials, this anticoagulant was at least as effective as previously known commercial anticoagulants when diluted by an additional 30%. The present anticoagulant preparation concentrate is an aqueous mixture of soft water (55.0%-65.0/%, w/w); tetrasodium ethylene diamine tetraacetate (Na4EDTA) (0.5%-3.0%, w/w); sodium hexametaphosphate (17.0%-24.0%, w/w); citric acid (5.0%-9.0%, w/w); and sodium hydroxide (4.0%-7.0%, w/w) to obtain a balanced pH that provides optimal chelating and anticoagulant activity. Optimal anticoagulant performance has been found to occur in the range of between pH 6.6 and pH 7.2.

Abstract: The invention deals with phosphate water solution with cold solidification capacity. Phosphate composition containing iron oxide solution in acid, water, advantages from the following properties; it contains orthophosphorus acid and in addition metal powder. Phosphate composition is ecologically pure product, non toxic, non cancerogenic, non-allergic. It has antimicrobial, antivirus and fungicidal properties. Phosphate composition can be applied within medicine: surgery, dermatology, dentistry, oncology, pharmacology and other branches. In agriculture use: as a means of curing plant diseases, within veterinary—as a means for preventive maintenance and curing of animal diseases, within construction—as an anticorrosive, fire-resistant, hydro-electric isolating covers, ceramic tiles, concretes, which protect against radiation, as well as for producing other composite materials.

Abstract: An acidic aqueous hydrogen peroxid solution is provided, with improved disinfectant activity. Concentrated solutions preferably contain up to about 8% and as-used concentrations contain about 0.5% peroxide. The solution also contains from 0.1 to 5.0% of at least one acid compound, e.g. phosphoric and/or a phosphonate with from 1 to 5 phosphonic acid groups, and from 0.02 to 5% of at least one anionic surfactant. The surfactant is selected from C8 to C16-alkyl aryl sulphonic acids, sulphonated C12 to C22 carboxylic acids, C8 to C22-alkyl diphenyl oxide sulphonic acids, naphthalene sulphonic acids, C8 to C22 alkyl sulphonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulphates, and mixtures thereof. Most preferably the solution has an emulsifier, e.g. a salt of an alkylated diphenyl oxide. The solution may also contain corrosion inhibitors and/or lower alcohols.

Abstract: A composite material is provided including a strongly bioresorbable, poorly crystalline apatitic calcium phosphate composite and a supplementary material. The poorly crystalline apatitic calcium phosphate is characterized in that, when placed in an intramuscular or subcutaneous site, resorption of at least 1 g of the material is complete within one year. The supplementary material is in intimate contact with the hydroxyapatite material in an amount effective to impart a selected characteristic to the composite. The supplemental material may be biocompatible, bioresorbable or non-resorbable.

Abstract: A method for restoration of the circadian rhythm of parathyroid hormone (PTH) serum levels in a subject having osteoporosis, so as to restore a circadian rhythm of PTH levels which is similar to that existing in normal subjects is disclosed by administering a single daily dose of a composition consisting essentially of an effective amount of phosphate in the evening or at night, whereby the composition causes a circadian rhythm of PTH levels which peaks during the night, whereby the circadian rhythm of PTH levels is restored to that which is similar to that existing in normal subjects, thereby treating osteoporosis.

Abstract: Nutritionally balanced dog food compositions containing a dietary source of pyrophosphate, for reducing the incidence and extent of hip joint subluxation in dogs, and method of use. One embodiment of the dog food composition includes about 2.0% by weight sodium acid pyrophosphate. In use and in one embodiment of the method a puppy is fed the dog food composition as substantially the sole diet from weaning at about 6-8 weeks of age to about 2 years of age, to improve hip joint stability and reduce the incidence and severity of canine hip dysplasia.

Abstract: A calcium-based ophthalmic composition for treating dry eye including a hydrophobic carrier, such as petrolatum, and a calcium salt. Also a method for treating dry eye comprising the step of administering the composition according to the present invention.

Abstract: Conditioning of the surface of silica-based glass or ceramic by differential immersion in a serum protein-containing solution, and the resultant microporous Ca—P surface layer having serum-protein like organic molecules, as defined herein intermingled throughout, is described.

Abstract: The present invention provides a novel process for converting a standard inert amorphous calcium phosphate precipitate into highly reactive amorphous solids. The amorphous solids can be used to react with other calcium phosphate solids to form a poorly-crystalline synthetic hydroxyapatite that provides both bioactivity and structural integrity. This novel amorphous material can be reacted with other calcium phosphates at or below 37° C. to form a bone-like material consisting of poorly crystalline hydroxyapatite.

Abstract: The invention relates to biocement pastes based on tricalcium phosphate and materials which are suitable for preventing or reducing the tendencies of the settable pastes to disintegrate and for improving their cohesion properties, with the result that improved processing of said pastes in the preparation of synthetic bone cements is ensured.

Abstract: Metal amino acid chelates for animals are beneficial for facilitating and promoting growth by increasing desired metallic ion uptake. The present invention is directed to a process for providing an animal fed additive by preparing metal amino acid chelates, and the metal amino acid chelate growth facilitator, promoter and enhancer prepared by the process.

Abstract: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer unbound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing skin care compositions comprising an absorption enhancer/micro-carrier.

Abstract: This invention relates to a weight control composition, preferably in the form of a capsule or tablet, comprising a mixture of guggul extract and at least one phosphate salt selected from calcium phosphate, potassium phosphate and sodium phosphate. The composition evidences synergistic activity in reducing body weight and percent body fat in mammals. The guggul extract/phosphate salt product also reduces plasma lipid levels and cholesterol in overweight hyperlipidaemic humans. The inventive composition may also contain at least one additional component selected from phosphatidylcholine, hydroxycitric acid and L-tyrosine.

Abstract: The present invention includes a process and composition for treating skin disorders. The composition of the present invention comprises 94.0 to 99.2 percent by weight of cation-free water, 0.1 to 1.0 percent by weight of Calcium chloride, 0.0 to 2.0 percent by weight of linear long chain polyphosphate, 0.1 to 1.0 percent by weight of sodium bicarbonate and 0.5 to 3.0 percent by weight of cross-linked polyacrylamide polymer.

Abstract: The invention provides a synthetic bone precursor material comprising amorphous calcium phosphate and a constituent that inhibits the crystallisation of calcium hydroxyapatite to amorphous calcium phosphate. The synthetic bone precursor may comprise a material of formula CaxMgyPO4 wherein Mg acts as an inhibitor for crystallisation. Other crystallisation inhibitors such as pyrophosphate may be present. The inhibitor is capable of dissolving in physiological saline. Loss of inhibitor from the precursor allows crystallisation of hydroxyapatite. The invention relates to use of a synthetic bone precursor to form bone in vivo, by a transformation of the amorphous precursor material to crystalline hydroxyapatite bone material by the leaching action on inhibitory ions body fluids. it is envisaged that the material will be useful in facilitating bone repair, inducing bone formation or assisting in the attachment of prostheses.

Abstract: A formed cream substitute for the addition to hot meals and a method for its preparation. The formed cream substitute for the addition to hot meals is formed by working 20 to 60% cream powder and 10 to 50% fat powder in a 15 to 50% matrix of pure fat. The cream substitute according to the invention can be provided in the form of lumps, in the form of cubes, or in the form of a granulate. The cream substitute can be stored well at room temperature and has, on a weight basis, a higher effectiveness than liquid cream.

Abstract: A flowable, paste-like composition capable of setting in a clinically relevant period of time into an antimicrobial agent loaded apatitic product having sufficient compressive strength to serve as a cancellous bone structural material is provided. The subject compositions are prepared by combining dry ingredients with a physiologically acceptable lubricant and an antimicrobial agent, where the dry ingredients comprise at least two different calcium phosphates. The subject compositions find use in a variety of different applications, including orthopaedic, dental and cranio-maxillofacial applications.

Abstract: A method of treating osteoporosis is disclosed by administering orally a single daily dosage of phosphate in the evening in an amount, e.g., about 10 mg/kg body weight or less which is effective to raise serum parathyroid hormone levels of the subject being treated.

Abstract: A calcium-based ophthalmic composition for treating dry eye is disclosed. The composition includes a hydrophobic carrier such as petrolatum and a calcium salt. The composition can further include a polyol such as glycerol, and an agent such as anhydrous lanolin, to enhance the interface between the carrier, and the calcium salt and polyol. Also disclosed is a method for treating dry eye comprising the step of administering the composition according to the present invention by placing the composition on the lateral portion of the lower eyelid margin. This method allows the composition to gradually disperse onto the cornea and conjunctiva.

Abstract: A composition for the treatment of premenstrual syndrome comprising an effective amount of calcium, magnesium, an analgesic and a diuretic sufficient to reduce the symptoms of premenstrual syndrome.

Abstract: An anticoagulant for blood contains sodium hydroxide, citric acid and sodium hexametaphosphate. A method of preventing the clotting of blood using the anticoagulant also is disclosed.

Abstract: Bath compositions comprising a complex powder comprising a water-soluble polymer and a water-soluble aluminum salt; and also a bath composition which comprises a complex powder containing a water-soluble polymer, a polyphosphoric acid or a salt thereof and a water-soluble aluminum salt. Such compositions provide a refreshing and comfortable sensation of dryness to the skin; do not form water-insoluble particles, agglomerates, or flocculants; and provide an agreeable appearance and a pleasant feeling to the bath water.

Abstract: A composition suitable for topical application to mammalian skin or hair for inducing, maintaining or increasing hair growth comprises:(i) a first chemical inhibitor chosen from proteoglycanase inhibitors, glycosaminoglycanase inhibitors, glycosaminoglycan chain cellular uptake inhibitors or mixtures thereof; and(ii) a cosmetically acceptable vehicle for the chemical inhibitor;provided that when the first chemical inhibitor is a weak inhibitor, such that a 1 mM aqueous solution of the inhibitor reduces proteoglycanase activity, glycosaminoglycanase activity or cellular uptake of glycosaminoglycan chains, by from 5 to 50%, in accordance with at least one of the assay tests as herein described, then there is also present in the composition a second chemical inhibitor and/or an activity enhancer. When minoxidil is the sole chemical inhibitor, then the activity enhancer is a penetration enhancer chosen from a limited number of materials, including certain esters and cationic polymers.

Abstract: A method of treating hypokalemia in a human by administering Kurrol's salt in an amount effective to elevate serum potassium of the human to the range of about 3.5 mmole/l to 5.5 mmole/l.

Abstract: Nuclear magnetic resonance imaging of animal or human tissue is enhanced when a paramagnetic pyrophosphate compound is administered intraveneously as a contrast agent. The contrast agent is particularly useful in magnetic resonance imaging of area of tissue calcification, such as acute myocardial infarctions. Specific localization of paramagnetic pyrophosphate in ischemic and necrotic muscle cells at the periphery of a myocardial infarction makes accurate localization and sizing of the central infarct and peri-infarct zones possible.